Imatinib mesylate, which is an effective drug for the treatment of chronic myeloid leukemia by targeting the dysregulated tyrosine kinase BCR-ABL, inhibits the phosphorylation of DRP1Ser616 with an IC50 of 0.97 ± 0.3 μM. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.